CN1093903A - A kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals - Google Patents

A kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals Download PDF

Info

Publication number
CN1093903A
CN1093903A CN93111213A CN93111213A CN1093903A CN 1093903 A CN1093903 A CN 1093903A CN 93111213 A CN93111213 A CN 93111213A CN 93111213 A CN93111213 A CN 93111213A CN 1093903 A CN1093903 A CN 1093903A
Authority
CN
China
Prior art keywords
pipemidic acid
pipemidic
reveals
normal saline
medicinal liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN93111213A
Other languages
Chinese (zh)
Other versions
CN1050994C (en
Inventor
李居富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zibo City No1 Hospital
Original Assignee
Zibo City No1 Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zibo City No1 Hospital filed Critical Zibo City No1 Hospital
Priority to CN93111213A priority Critical patent/CN1050994C/en
Publication of CN1093903A publication Critical patent/CN1093903A/en
Application granted granted Critical
Publication of CN1050994C publication Critical patent/CN1050994C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is a kind of treatment diarrheal coloclysis medicinal liquid, mainly contains the pipemidic acid sheet, can be the mixture of pipemidic acid, normal saline, alkali, also can be the mixture of pipemidic acid and glycerol.The present invention has changed route of administration, and medicine directly acts on diseased region, more can bring into play powerful sterilization, bacteriostasis than systemic administration, has avoided the antibiotic toxicity, side effect of systemic administration simultaneously.The bacillary dysentery, enteritis, ulcerative colitis etc. that to treatment with diarrhoea are primary symptom have tangible curative effect, cure rate height.

Description

A kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals
The present invention is a kind of treatment diarrheal coloclysis medicinal liquid, mainly contains pipemidic acid.
The disease that with diarrhoea is primary symptom is more common in cellularity dysentery, enteritis, ulcerative colitis etc.To these treatment of diseases, all with oral, intramuscular injection or intravenous drip antibiotic, Claritin is main, but the not good enough chronic disease that develops into of curative effect sometimes is not easy radical cure and causes suffering to patient.And above-mentioned Therapeutic Method all has certain difficulty for child patient.Use antibiotic too much simultaneously, be easy to generate poison, pay reaction.As the pipemidic acid tablet is oral medication, and treatment diarrhoea is had certain curative effect, but for than the severe disease feelings, curative effect is relatively poor.
The object of the present invention is to provide a kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid to reveal, change route of administration, overcome the shortcoming of systemic administration, to treatment diarrhoea curative effect height, cure rate height.
The objective of the invention is to realize in the following way:
Treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals, and comprises the pipemidic acid powder, normal saline and alkali.
Purpose of the present invention can also realize in the following way:
It is 9-10.5 that the addition of alkali makes the PH of medicinal liquid, the one, increased the dissolubility of pipemidic acid, and the 2nd, make medicinal liquid present advantages of higher stability.Alkali can be selected NaOH or NaHCO for use 3Saturated solution adopts the PH reagent paper can measure pH value very easily.
Comprise pipemidic acid 0.5-1.5g in the 50ml normal saline, optimised quantity is 0.5-1.0g.
Pipemidic acid of the present invention preferably adds antiseptic in revealing, and to increase stability of drug, makes the storage of its energy long period, and antiseptic is the 0.01-0.02 gram in the 50ml normal saline.
A kind of better embodiment of the present invention is the pipemidic acid that adds 0.5-1.5g in the 50ml normal saline, 0.01-0.02g antiseptic, PH is 9-10.5, antiseptic can be selected nipalgin for use, the optimised quantity that pipemidic acid adds is the 0.5-1.0 gram, and the described mix homogeneously of respectively forming gets final product.
Purpose of the present invention can also realize in the following way:
The treatment diarrheal is irritated decoction liquid pipemidic acid and is revealed, and comprises pipemidic acid and glycerol, is good to contain pipemidic acid 0.5-1.5g in the 50ml glycerol.
Glycerol has the healing of the ulcer surface of promotion, and antisepsis has special efficacy to the treatment ulcerative colitis behind the adding pipemidic acid.
By the present invention, some other antibiolics also can adopt form of the present invention to treat disease.
Advantage of the present invention:
<1 〉, the present invention is a kind of enema, directly acts on diseased region-colon after the medicine coloclysis, and the colonic drug level is increased, the efficacy of a drug is concentrated, more can bring into play bigger sterilization, bacteriostasis than systemic administration, avoid systemic administration simultaneously, antibiotic poison, pair effect.
<2 〉, the present invention makes simply, and is easy to use, basic hospital, clinic, patient can use under family members help.It is uncooperative particularly to have solved the child patient oral medication, fears the problem of pin.
<3 〉, the pipemidic acid that contains pipemidic acid, normal saline, alkaline matter be exposed at bring down a fever, pain relieving, antidiarrheal, the multiple normal aspects curative effect of stool all is significantly improved than systemic administration.
<4 〉, the present invention except that having anti-infectious function, can also help to discharge intravital part toxin, the effect that alleviates the whole body poisoning symptom is arranged.
<5 〉, by matched group relatively, the present invention has tangible raising to being that the bacillary dysentery, enteritis, ulcerative colitis etc. of primary symptom have good curative effect with diarrhoea than systemic administration.
Case one:
Open * *, man, 60 years old, retired worker.It is surplus to suffer from chronic bacillary dysentery 8 years, recurs whenever fatigue, cold drinks and snachs, climate change, all invalid with multiple antibiotic and Chinese medicine.Mainly show as: stomachache, diarrhoea, passage of loose stools band dope, weak, lack of appetite.Through being produce effects 2 times with the present invention's (containing pipemidic acid, normal saline, alkaline matter) coloclysis, transference cure after 6 times, promptly and reuse is consolidated curative effect for 20 times, drug withdrawal is not recurred later six months again.
Case two:
Zhai * *, woman, 57 years old.Year surplus because of stomachache, diarrhoea, the per rectum spectroscopy is diagnosed as ulcerative colitis, the oral administration norfloxacin, and pipemidic acid, the coloclysis metronidazole, prednisone, gentamycin etc. are all invalid.Through with produce effects after the coloclysis of the present invention 6 times, stomachache disappears, diarrhoea again.After again coloclysis consolidate curative effect 20 times, now 5 months, recurrence again.
Embodiment one:
Pipemidic acid powder 0.75g, PH=9, normal saline 50ml
Being pipemidic acid after said medicine is mixed reveals.
Embodiment two:
Pipemidic acid powder 0.5g, PH=9.8, normal saline 50ml, nipalgin 0.015g.
Embodiment three:
The 50ml normal saline, pipemidic acid 1.5g, PH=10.5, nipalgin 0.01g.
Embodiment four:
The 50ml normal saline, pipemidic acid 1.0g, PH=10, nipalgin 0.02g.
Embodiment five:
50ml glycerol, pipemidic acid powder 0.5g
Embodiment six:
50ml glycerol, pipemidic acid powder 1.5g

Claims (11)

1, a kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals, and it is characterized in that comprising pipemidic acid powder, normal saline and alkali.
2, pipemidic acid according to claim 1 reveals, and is characterised in that PH is 9-10.5.
3, reveal according to claim 1,2 described pipemidic acids, be characterised in that to comprise pipemidic acid powder 0.5-1.5g in the 50ml normal saline.
4, pipemidic acid according to claim 3 reveals, and the optimised quantity that is characterised in that described pipemidic acid is 0.5-1.0g.
5, reveal according to claim 1,2 described pipemidic acids, be characterised in that described alkali can adopt NaOH or saturated NaHCO 3Solution.
6, reveal according to claim 1,2 described pipemidic acids, be characterised in that also to comprise antiseptic.
7, pipemidic acid according to claim 6 reveals, and is characterised in that to comprise pipemidic acid 0.5-1.5g, antiseptic 0.01-0.02g in the 50ml normal saline.
8, pipemidic acid according to claim 6 reveals, and is characterised in that to comprise pipemidic acid 0.5-1.5g in the 50ml normal saline that nipalgin 0.01-0.02g, PH are 9-10.5.
9, pipemidic acid according to claim 8 reveals, and is characterised in that preferred compositing range is to comprise in the 50ml normal saline that pipemidic acid 0.5-1.0g, 0.01-0.02g nipalgin, PH are 9-10.5.
10, a kind of treatment diarrheal is irritated decoction liquid pipemidic acid dew, is characterised in that to comprise pipemidic acid powder and glycerol.
11, pipemidic acid according to claim 10 reveals, and is characterised in that and contains pipemidic acid 0.5-1.5g in the 50ml glycerol.
CN93111213A 1993-04-24 1993-04-24 Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea Expired - Fee Related CN1050994C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN93111213A CN1050994C (en) 1993-04-24 1993-04-24 Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN93111213A CN1050994C (en) 1993-04-24 1993-04-24 Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea

Publications (2)

Publication Number Publication Date
CN1093903A true CN1093903A (en) 1994-10-26
CN1050994C CN1050994C (en) 2000-04-05

Family

ID=4989016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93111213A Expired - Fee Related CN1050994C (en) 1993-04-24 1993-04-24 Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea

Country Status (1)

Country Link
CN (1) CN1050994C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048730C (en) * 1998-04-23 2000-01-26 河南省新乡市第二人民医院 Zinc pipemidate its synthetic process and zinc pipemidate ointment
CN105250305A (en) * 2015-10-13 2016-01-20 康普药业股份有限公司 Pipemidic acid pharmaceutical composition
CN111700907A (en) * 2020-07-24 2020-09-25 安徽克瑞迪医疗科技有限公司 Liquid dressing and configuration method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048730C (en) * 1998-04-23 2000-01-26 河南省新乡市第二人民医院 Zinc pipemidate its synthetic process and zinc pipemidate ointment
CN105250305A (en) * 2015-10-13 2016-01-20 康普药业股份有限公司 Pipemidic acid pharmaceutical composition
CN111700907A (en) * 2020-07-24 2020-09-25 安徽克瑞迪医疗科技有限公司 Liquid dressing and configuration method

Also Published As

Publication number Publication date
CN1050994C (en) 2000-04-05

Similar Documents

Publication Publication Date Title
US5427799A (en) Sustained release composition and method utilizing xanthan gum and an active ingredient
US5102666A (en) Calcium polycarbophil controlled release composition and method
Breuer et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report
US5686094A (en) Controlled release formulations for the treatment of xerostomia
DE69434490T2 (en) Compilations for cancer treatment
DE2908847C3 (en) Delayed release pharmaceutical preparation
US5110605A (en) Calcium polycarbophil-alginate controlled release composition and method
DE69330180T2 (en) FORMULATIONS CONTAINING HYALURONIC ACID
DE69430903T2 (en) TREATMENT OF PERIODONTITIS WITH MISOPROSTOL
DE69612755T2 (en) TRIGLYCERIDES AND ETHYLESTERS OF PHENYLALKOIC ACIDS AND PHENYLALKOIC ACIDS FOR THE TREATMENT OF VARIOUS DISEASES
CN1050994C (en) Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea
JPH03246233A (en) Drug composition for transmucosal administration
Euler et al. Failure of a cytoprotective dose of arbaprostil to heal acute duodenal ulcers: results of a multiclinic trial
CN1058154C (en) Medicine for treatment of pile
EP1156831A1 (en) Hydroxyethy starch for the painless and tissue-conserving injection of medicaments
DE19732323C2 (en) Drug combination for increased drug concentration in tissues
CN101053598B (en) Medicinal composition for treating cardio-cerebralvascular diseases and diabetes
CN1663600B (en) Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application
DE60216453T2 (en) USE OF ANTI-DIABETICS FOR THE PREPARATION OF A TREATMENT-DRIVING MEDICAMENT
CN1289144C (en) Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis
JPS63196517A (en) Antihypoxic and application
CA2259773A1 (en) Antifibrotic agent
CN1399957A (en) Application of shikonin and its derivative in pharmaceutical industry
CN110354136A (en) A kind of Sodium Aescinate compound buccal lozenge and preparation method thereof for treating canker sore
CN1117563C (en) Analgesic composition for cancers in digestive system

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee